Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Vosoritide for Selected Genetic Causes of Short Stature

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04219007
Recruitment Status : Recruiting
First Posted : January 6, 2020
Last Update Posted : June 19, 2020
Sponsor:
Information provided by (Responsible Party):
Andrew Dauber, Children's National Research Institute

Brief Summary:
Short stature can be caused by a number of genetic etiologies, many of which directly affect the growth plate. The FGFR3/CNP pathway is central to growth of the chondrocyte. The study team hypothesizes that patients with selected genetic causes of short stature that interact with this pathway will benefit from treatment with vosoritide, a CNP analog, a selective NPR-B agonist which directly targets the growth plate. This study will enroll patients with short stature in selected genetic categories and will follow them for a 6 month observation period to obtain a baseline growth velocity, safety profile and quality of life assessment. Patients will then be treated with vosoritide for 12 months and will be assessed for safety monitoring and improvement in height outcomes.

Condition or disease Intervention/treatment Phase
Short Stature Drug: Vosoritide Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 35 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Vosoritide for Selected Genetic Causes of Short Stature
Estimated Study Start Date : July 15, 2020
Estimated Primary Completion Date : January 1, 2023
Estimated Study Completion Date : June 1, 2023


Arm Intervention/treatment
Experimental: Genetic Short Stature

Vosoritide, also known as BMN 111 or modified recombinant human C-type natriuretic peptide (CNP), is a 39-amino-acid peptide analog that includes the 37 C-terminal amino acids of the human CNP53 sequence plus the addition of 2 amino acids (Pro-Gly) on the N-terminus. This structural modification conveys resistance to neutral endopeptidase (NEP) degradation, resulting in prolonged half-life (t1/2) in comparison to endogenous CNP. This increase in t1/2 allows once daily subcutaneous (SC) administration.

Vosoritide will be administered as a single 15 μg/kg subcutaneous injection given daily for 12 months.

Drug: Vosoritide
After enrollment, subjects will be followed for a 6 month observation only period to establish a baseline height velocity as well as safety profile and quality of life assessment. Vosoritide will then be administered daily via subcutaneous injection at a dose of 15 µg/kg/day for 12 months.
Other Name: BMN-111




Primary Outcome Measures :
  1. Incidence of Treatment Emergent Adverse Events [Safety and Tolerability] [ Time Frame: 12 months ]
    Number of treatment-emergent adverse events or serious adverse events per study participant

  2. Incidence of Symptomatic Hypotension events [Safety and Tolerability] [ Time Frame: 12 months ]
    Number of symptomatic hypotension events per study participant

  3. Change from Baseline in annualized growth velocity [ Time Frame: 12 months ]
    To evaluate the change from baseline in age-sex standardized annualized growth velocity in cm/year after 12 months of daily SC injections of vosoritide in patients with selected genetic causes of short stature.

  4. Change from Baseline in standardized height SDS [ Time Frame: 12 months ]
    To evaluate the change from baseline in age-sex standardized height SDS after 12 months of daily SC injections of vosoritide in patients with selected genetic causes of short stature.


Secondary Outcome Measures :
  1. Changes in the seated height ratio as a measure of body proportions [ Time Frame: 12 months ]
    To evaluate the seated height ratio (expressed as a percentage) as a measure of body proportions. Measurement after 12 months of treatment will be compared to baseline.

  2. Changes in the difference between arm span and height from baseline [ Time Frame: 12 months ]
    To evaluate the difference between arm span and height (measured as cm) as a measure of body proportions. Measurement after 12 months of treatment will be compared to baseline.

  3. Changes from Baseline in bone age/chronological age [ Time Frame: 12 months ]
    To evaluate changes from baseline in bone age/chronological age after 12 months of daily SC injections of vosoritide


Other Outcome Measures:
  1. Characterize the area under the plasma concentration time-curve from time 0 to infinity (AUC0-∞) [ Time Frame: 3 hours at each visit ]
    Estimated by non-compartmental analysis for Day 1, 6 months, and 12 months per study participant

  2. Characterize the area under the plasma concentration-time curve from 0 to the time of last measurable concentration (AUC0-t) [ Time Frame: 3 hours at each visit ]
    Estimated by non-compartmental analysis for Day 1, 6 months, and 12 months per study participant

  3. Characterize maximum concentration (Cmax) of vosoritide in plasma [ Time Frame: 3 hours at each visit ]
    Estimated by non-compartmental analysis for Day 1, 6 months, and 12 months per study participant

  4. Characterize the elimination half-life of vosoritide (t½) [ Time Frame: 3 hours at each visit ]
    Estimated by non-compartmental analysis for Day 1, 6 months, and 12 months per study participant

  5. Characterize the apparent clearance of drug (CL/F) [ Time Frame: 3 hours at each visit ]
    Estimated by non-compartmental analysis for Day 1, 6 months, and 12 months per study participant

  6. Characterize the apparent volume of distribution based upon the terminal phase (Vz/F) [ Time Frame: 3 hours at each visit ]
    Estimated by non-compartmental analysis for Day 1, 6 months, and 12 months per study participant

  7. Changes from Baseline in bone mineral density [ Time Frame: 12 months ]
    To evaluate changes from baseline in bone mineral density (BMD) after 12 months of daily SC injections of vosoritide (expressed as height adjusted Z-score).

  8. Evaluate immunogenicity and assess impact on safety and efficacy measures [ Time Frame: 12 months ]
    To evaluate immunogenicity and assess impact on safety and efficacy measures after 12 months of daily SC injections of vosoritide as evidenced by rates of vosoritide antibody development, which is a standard safety metric.

  9. Changes from baseline in quality of life after daily SC injections of vosoritide: Quality of Life of Short Stature Youth (QoLISSY) questionnaire score is expressed as a percentage [ Time Frame: 12 months ]
    To evaluate changes from baseline in quality of life using the QoLISSY scale after 12 months of daily SC injections of vosoritide. The Quality of Life of Short Stature Youth (QoLISSY) questionnaire score is expressed as a percentage, with scores ranging from 0% to 100% (100% is the best score).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   3 Years to 10 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Parent(s) or guardian(s) are willing and able to provide written, signed informed consent after the nature of the study has been explained and prior to performance of any research-related procedure. Also, subjects under the age of 18 are willing and able to provide assent (if required) after the nature of the study has been explained and prior to performance of any research-related procedure.
  2. Stated willingness to comply with all study procedures and availability for the duration of the study
  3. Age >3 years 0 days AND <10 years 364 days for males, <9 years 364 days for females
  4. Pre-pubertal defined as Tanner Stage 1 breasts in females and testicular volumes <3 cc in males. This must be confirmed at the Day 1 visit prior to initiation of vosoritide.
  5. Patient height <-2.25 SDS. All height SDS values are calculated using the CDC growth charts/data tables (40).
  6. Patients with pathogenic or likely pathogenic variants in genes known to cause the specific genetic subgroups of short stature listed below are eligible for inclusion in the study. Pathogenicity of variants will be classified as per the American College of Medical Genetics criteria (41). Documentation of the presence of the variant must be obtained using a lab results report from a CLIA certified laboratory. Classification of the variant's pathogenicity status will be performed by the Children's National study team.

    A. CNP deficiency due to mutations in NPPC - Subjects with heterozygous or homozygous defects in NPPC are eligible.

    B. Hypochondroplasia - Subjects with heterozygous variants in FGFR3 gene associated with hypochondroplasia are eligible. Subjects with variants in FGFR3 known to cause achondroplasia or thanatophoric dysplasia or SADDAN syndrome will be excluded.

    C. Patients with heterozygous defects in NPR2 are eligible. Patients with homozygous defects in NPR2 will be excluded.

    D. Rasopathy patients (including Noonan syndrome, Costello syndrome, Cardiofaciocutaneous syndrome, Neurofibromatosis Type 1) - This include patients with heterozygous variants in the following genes:

    i. BRAF ii. CBL iii. HRAS iv. KRAS v. LZTR1 vi. MAP2K1 vii. MAP2K2 viii. MRAS ix. NF1 x. NRAS xi. PPP1CB xii. PTPN11 xiii. RAF1 xiv. RRAS xv. RIT1 xvi. SHOC2 xvii. SOS1 xviii. SOS2

    E. Patients with SHOX deficiency - Patients with heterozygous defects in SHOX including patients with heterozygous deletions of the SHOX regulatory region known to cause SHOX deficiency.

  7. Absence of growth hormone deficiency defined as an IGF-1 level above the lower limit of the normal range of the assay. If a patient has an IGF-1 level below the lower limit of the normal range of the assay, two growth hormone stimulation tests must be performed using the routine local protocols. Patients with a peak growth hormone level >7 ng/ml will be considered growth hormone sufficient and will be eligible for inclusion as per the Growth Hormone Research Society International consensus (42). If indicated based on IGF-1 level from the referring clinician, the growth hormone stimulation test must be done as part of routine clinical care prior to enrollment. The rationale for using an IGF-1 below the normal range as the cut-off for further evaluation for growth hormone deficiency is that in patients with a clear genetic explanation for their short stature, an IGF-1 level anywhere within the normal range would be considered reassuring and would not lead to a growth hormone stimulation test in a routine clinical setting.
  8. The subject and their guardian must speak one of the 11 languages for which the QoLISSY survey (a quality of life survey for short stature) is available. These include: English, Spanish, German, Russian, Swedish, Flemish, Italian, Turkish, French, Japanese, and Ukrainian.

Exclusion Criteria:

  1. Growth plate fusion - Defined as a bone age via the Greulich and Pyle method of 13 years in females and 15 years in males. These patients have limited remaining growth potential.
  2. Concomitant treatment with growth hormone or recombinant IGF-1. Patients may have been previously treated with growth hormone or IGF-1 therapy. If the patient is currently on one of these therapies, they will be required to discontinue treatment in order to begin the baseline observation period for this trial. That decision will be deferred to their treating clinical endocrinologists in conjunction with the patient's guardians. We anticipate that only patients who are having a poor response to their therapy will be interested in enrolling in the current study as there is no rationale for a patient who is receiving growth hormone therapy and having a positive response to enroll in the current study.
  3. Prior treatment with a GnRH analog, aromatase inhibitor or oxandrolone
  4. History of any type of malignancy
  5. Chronic medical condition known to affect growth including but not limited to:

    A. Cystic fibrosis B. Diabetes C. Inflammatory Bowel Disease D. Celiac Disease E. Asthma requiring a daily inhaled steroid dose > 400 micrograms of inhaled budesonide per day or equivalent F. Taking daily oral glucocorticoids for any reason G. Note - ADHD treated with a stimulant and treated hypothyroidism with a normal TSH will NOT exclude the subject from participating in the trial.

    H. Turner Syndrome or any other chromosomal aneuploidy I. Congenital heart disease which places the subject at increased risk of an adverse cardiac outcome in the setting of hypotension including but not limited to: hypertrophic cardiomyopathy, aortic stenosis with peak gradient >50mmHg, severe aortic regurgitation (defined as pressure half time >500ms by echocardiogram), coronary insufficiency, or any anatomy with a need for an afterload reducing agent. Any patient with baseline abnormalities on echocardiogram will be reviewed with a pediatric cardiologist for appropriateness for inclusion in the study.

  6. Malnutrition - Defined as a BMI <5th percentile (CDC growth charts)
  7. Any clinically significant abnormality on screening tests as determined by the principal investigator
  8. Known or suspected allergy to trial medication, excipients, or related products
  9. The receipt of any investigational drug within 90 days prior to this trial

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04219007


Contacts
Layout table for location contacts
Contact: Andrew Dauber, MD MMSc 202-476-2121 adauber@childrensnational.org
Contact: Kimberly Boucher 202-476-1403 kboucher@childrensnational.org

Locations
Layout table for location information
United States, District of Columbia
Children's National Hospital Recruiting
Washington, District of Columbia, United States, 20010
Contact: Tara McCarthy    202-476-6894    tmccarthy@childrensnational.org   
Sponsors and Collaborators
Andrew Dauber
Investigators
Layout table for investigator information
Principal Investigator: Andrew Dauber, MS MMSc Children's National Research Institute
Layout table for additonal information
Responsible Party: Andrew Dauber, Chief of Endocrinology, Children's National Research Institute
ClinicalTrials.gov Identifier: NCT04219007    
Other Study ID Numbers: Pro00013585
First Posted: January 6, 2020    Key Record Dates
Last Update Posted: June 19, 2020
Last Verified: June 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Andrew Dauber, Children's National Research Institute:
Hypochondroplasia
SHOX Deficiency
Rasopathy
NPR2
CNP
Noonan Syndrome
Additional relevant MeSH terms:
Layout table for MeSH terms
Dwarfism
Bone Diseases, Developmental
Bone Diseases
Musculoskeletal Diseases
Genetic Diseases, Inborn
Endocrine System Diseases